193 related articles for article (PubMed ID: 1534977)
1. In vitro activities of three semisynthetic amide derivatives of teicoplanin, MDL 62208, MDL 62211, and MDL 62873.
Biavasco F; Lupidi R; Varaldo PE
Antimicrob Agents Chemother; 1992 Feb; 36(2):331-8. PubMed ID: 1534977
[TBL] [Abstract][Full Text] [Related]
2. In-vitro activity of vancomycin, teicoplanin, daptomycin, ramoplanin, MDL 62873 and other agents against staphylococci, enterococci and Clostridium difficile.
Bartoloni A; Colao MG; Orsi A; Dei R; Giganti E; Parenti F
J Antimicrob Chemother; 1990 Nov; 26(5):627-33. PubMed ID: 1688341
[TBL] [Abstract][Full Text] [Related]
3. Activities of two new teicoplanin amide derivatives (MDL 62211 and MDL 62873) compared with activities of teicoplanin and vancomycin against 800 recent staphylococcal isolates from France and the United States.
Jones RN; Goldstein FW; Zhou XY
Antimicrob Agents Chemother; 1991 Mar; 35(3):584-6. PubMed ID: 1828137
[TBL] [Abstract][Full Text] [Related]
4. In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide.
Biavasco F; Vignaroli C; Lupidi R; Manso E; Facinelli B; Varaldo PE
Antimicrob Agents Chemother; 1997 Oct; 41(10):2165-72. PubMed ID: 9333042
[TBL] [Abstract][Full Text] [Related]
5. Antimicrobial activity of MDL 62,873, a semisynthetic derivative of teicoplanin, in vitro and in experimental infections.
Berti M; Candiani G; Borgonovi M; Landini P; Ripamonti F; Scotti R; Cavenaghi L; Denaro M; Goldstein BP
Antimicrob Agents Chemother; 1992 Feb; 36(2):446-52. PubMed ID: 1534978
[TBL] [Abstract][Full Text] [Related]
6. Comparative in vitro activity of LY146032 (daptomycin), a new lipopeptide antimicrobial.
Hodinka RL; Jack-Wait K; Wannamaker N; Walden TP; Gilligan PH
Eur J Clin Microbiol; 1987 Feb; 6(1):100-3. PubMed ID: 3032607
[TBL] [Abstract][Full Text] [Related]
7. Antistaphylococcal and antienterococcal activity of the new teicoplanin amide derivative MDL 62873.
Qadri SM; Saldin H; Ueno Y
Chemotherapy; 1993; 39(1):55-8. PubMed ID: 8444061
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of teicoplanin and vancomycin against gram-positive bacteria from human clinical and veterinary sources.
Jensen KT; Schønheyder H; Pers C; Thomsen VF
APMIS; 1992 Jun; 100(6):543-52. PubMed ID: 1535201
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the in-vitro activity of the glycopeptide antibiotic LY333328 in comparison with vancomycin and teicoplanin.
Harland S; Tebbs SE; Elliott TS
J Antimicrob Chemother; 1998 Feb; 41(2):273-6. PubMed ID: 9533471
[TBL] [Abstract][Full Text] [Related]
10. European Glycopeptide Susceptibility Survey of gram-positive bacteria for 1995. European Glycopeptide Resistance Survey Study Group.
Felmingham D; Brown DF; Soussy CJ
Diagn Microbiol Infect Dis; 1998 Aug; 31(4):563-71. PubMed ID: 9764397
[TBL] [Abstract][Full Text] [Related]
11. [In vitro activity of vancomycin and teicoplanin against gram-positive cocci].
Bezian MC; Ribou G; Masquelier B
Pathol Biol (Paris); 1992 May; 40(5):461-5. PubMed ID: 1386667
[TBL] [Abstract][Full Text] [Related]
12. Resistance to vancomycin and teicoplanin: an emerging clinical problem.
Johnson AP; Uttley AH; Woodford N; George RC
Clin Microbiol Rev; 1990 Jul; 3(3):280-91. PubMed ID: 2143434
[TBL] [Abstract][Full Text] [Related]
13. Antimicrobial activity of MDL 63,246, a new semisynthetic glycopeptide antibiotic.
Goldstein BP; Candiani G; Arain TM; Romanò G; Ciciliato I; Berti M; Abbondi M; Scotti R; Mainini M; Ripamonti F
Antimicrob Agents Chemother; 1995 Jul; 39(7):1580-8. PubMed ID: 7492108
[TBL] [Abstract][Full Text] [Related]
14. New semisynthetic glycopeptides MDL 63,246 and MDL 63,042, and other amide derivatives of antibiotic A-40,926 active against highly glycopeptide-resistant VanA enterococci.
Malabarba A; Ciabatti R; Scotti R; Goldstein BP; Ferrari P; Kurz M; Andreini BP; Denaro M
J Antibiot (Tokyo); 1995 Aug; 48(8):869-83. PubMed ID: 7592033
[TBL] [Abstract][Full Text] [Related]
15. Endophthalmitis: gram positive ethiological agents and susceptibility to glycopeptides.
Chisari G
Curr Clin Pharmacol; 2008 Sep; 3(3):153-5. PubMed ID: 18781901
[TBL] [Abstract][Full Text] [Related]
16. Activities of the semisynthetic glycopeptide LY191145 against vancomycin-resistant enterococci and other gram-positive bacteria.
Nicas TI; Mullen DL; Flokowitsch JE; Preston DA; Snyder NJ; Stratford RE; Cooper RD
Antimicrob Agents Chemother; 1995 Nov; 39(11):2585-7. PubMed ID: 8585753
[TBL] [Abstract][Full Text] [Related]
17. Clinical relevance of a European collaborative study on comparative susceptibility of gram-positive clinical isolates to teicoplanin and vancomycin.
Grüneberg RN; Hryniewicz W
Int J Antimicrob Agents; 1998 Nov; 10(4):271-7. PubMed ID: 9916900
[TBL] [Abstract][Full Text] [Related]
18. The in vitro activity of ramoplanin (A-16686/MDL 62,198), vancomycin and teicoplanin against methicillin-susceptible and methicillin-resistant Staphylococcus spp.
O'Hare MD; Felmingham D; Grüneberg RN
Drugs Exp Clin Res; 1988; 14(10):617-9. PubMed ID: 2977587
[TBL] [Abstract][Full Text] [Related]
19. Development of in-vitro resistance to glycopeptide antibiotics: assessment in staphylococci of different species.
Biavasco F; Giovanetti E; Montanari MP; Lupidi R; Varaldo PE
J Antimicrob Chemother; 1991 Jan; 27(1):71-9. PubMed ID: 1828799
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of teicoplanin, vancomycin, A16686, clindamycin, erythromycin and fusidic acid against anaerobic bacteria.
Hassan H; O'Hare MD; Felmingham D
Singapore Med J; 1990 Feb; 31(1):56-8. PubMed ID: 2139737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
